Olink

Olink®
Part of Thermo Fisher Scientific

BCG vaccination-induced acquired control of mycobacterial growth differs from growth control preexisting to BCG vaccination

Nature Communications, 2024

van Meijgaarden K., Li W., Moorlag S., Koeken V., Koenen H., Joosten L., Vyakarnam A., Ahmed A., Rakshit S., Adiga V., Ottenhoff T., Li Y., Netea M., Joosten S.

Disease areaApplication areaSample typeProducts
Infectious Diseases
Pathophysiology
Plasma
Olink Target 96

Olink Target 96

Abstract

Bacillus Calmette-Guèrin – vaccination induces not only protection in infants and young children against severe forms of tuberculosis, but also against non-tuberculosis related all-cause mortality. To delineate different factors influencing mycobacterial growth control, here we first investigate the effects of BCG-vaccination in healthy Dutch adults. About a quarter of individuals already control BCG-growth prior to vaccination, whereas a quarter of the vaccinees acquires the capacity to control BCG upon vaccination. This leaves half of the population incapable to control BCG-growth. Single cell RNA sequencing identifies multiple processes associated with mycobacterial growth control. These data suggest (i) that already controllers employ different mechanisms to control BCG-growth than acquired controllers, and (ii) that half of the individuals fail to develop measurable growth control irrespective of BCG-vaccination. These results shed important new light on the variable immune responses to mycobacteria in humans and may impact on improved vaccination against tuberculosis and other diseases.

Read publication ↗